InvestorsHub Logo
Followers 69
Posts 7941
Boards Moderated 0
Alias Born 01/29/2015

Re: None

Monday, 05/16/2022 1:55:31 PM

Monday, May 16, 2022 1:55:31 PM

Post# of 16729
Re: Discussion from AGNPF Yahoo msg board

@tcmoiba That's absolutely nuts! You are advocating for yet more dilution where $30 is already the break even point for pre split shares. Absolutely bonkers idea. The stock will already be luck to trade above $3 once uplisted. Do simple math. They are selling more than half the company for $8 million. That means the current market cap of $6 million to $7 millions is what the market believes the company is worth. Adding $8 million to run clinical trials doesn't increase the overall value at Phase 1. So here's more simple math ... Take the current market cap of 6 million and add the 8 million capital raise. That puts you at 14 million market cap. Divide the 14 million by 3.5 million shares outstanding. That leaves you with a share price of $4 USD. Now go look at XRTX where they recently uplisted and Algernon's CEO compares Algernon's uplist to. XRTX is trading at sub $2 per share at less than 20 million market cap and they are already conducting clinical trials. That's where Algernon is headed on the Nasdaq. This stock is prime for getting the #$%$ shorted out if it like never before in penny world. Live and Learn the Hard Way.

__________________________

IMO, Christopher Moreau can remain on his webcast crusade but it's not going to do a damn thing for the share price at Phase 1. Surely, he will be in a - forget about the past - mode and barrel ahead head first towards another cliff.

The best thing they could do with that 8 million is doend it all on a standalone Chronic Cough clinical trial powered for statistical significance and conducted in North America That is Algernon's best and likely OBLY true shot at getting shareholders back to even @ $30 per share. Will that happen...of course not. They are too busy diluting the company for pie in the sky BS and flavor of the month angles. Before it was covid...now it's psychedelics. Once they drive the bus over the next cliff they will be onto whatever else becomes a hot topic. Meanwhile, Bellus Health is rolling up their sleeves and doing real world pharma deals not virtual reality management shit - phoning it in.

M$